O. Băjenaru *
Conf. Dr. Ovidiu Băjenaru – șef Clinica Neurologie – Spitalul Universitar București
Abstract
Atherotrombosis is by its major complications (ischemic heart disease, stroke and peripheral arteries disease) the first cause of morbidity and mortality in the developed countries. The prophilaxy of these complications, in particular of the cervico-cerebral arteries, must therefore be directed against the risk factors of atherosclerosis (or to limit their effects, as long as a part of them are genetically conditioned) and, on the other hand against the pathogenetic mechanisms (better known during the last years), leading to the increase of the vulnerability of the atherom plaque to fracture, which triggers the thrombogenesis by platelet aggergation: local and systematic inflamatory changes, smooth muscle cells proliferation; the local expression of cellular adhesion molecules play a central role in this pathogenic process. The experimental and clinical studies have proved the efficiency in the prophylaxy of the cervico-cerebral arteries atherothrombosis of some drugs as: the HMG-CoA reductase inhibitors, angiotensin conversion enzyme inhibitors, angiotensin II receptors inhibitors, and platelet aggregation inhibitors (aspirin and clopidogrel).